港股创新药调整期真的来了?维立志博董事长康小强:不会将注意力集中于“追风”

每日经济新闻
Oct 30

今年国庆中秋假期前后,Biotech(生物科技公司)再次在港交所排起了长龙,而错峰递表的维立志博(HK09887,股价57.00港元,市值113.37亿港元)赶在7月完成了公司的“上市礼”。7月25日,当维立志博创始人康小强敲响铜锣,中国“TCE(T细胞衔接器)第一股”就此诞生。  在业内,TCE远没有ADC(抗体偶联药物)的名气大。它也像一枚生物导弹,通过连接人体内的T细胞和表达选定表面标志物的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10